Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,481 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Various Clear all
Completed Phase 1Phase 2 Interventional Results available

A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma

NCT01781572
View directory record Official record
Conditions
Locally Advanced or Metastatic NRAS Mutant Melanoma
Interventions
LEE011, MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
San Francisco, California • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of a Web-Based Behavioral Intervention on Physical Activity Levels in Adolescents

NCT01433679
View directory record Official record
Conditions
Health Behavior, Adolescent Behavior, Motivation
Interventions
Zamzee Intervention
Behavioral
Lead sponsor
HopeLab Foundation
Other
Eligibility
11 Years to 14 Years
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Osos, California • Oakland, California • Pismo Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Belongingness in Nursing Through Mindfulness - BEING Mindful: A Pilot Study

NCT06866288
View directory record Official record
Conditions
Mindfulness, Sense of Belonging
Interventions
Meditation, Yoga
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Investigating Electrical Categorical Loudness Scaling Using a Mobile Research App in Experienced Adult Cochlear Implant Participants

NCT07077070
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
Standard Electrical Categorical Loudness Scaling task (Standard-ELS), Fast Electrical Categorical Loudness Scaling task (Fast-ELS)
Device
Lead sponsor
Cochlear
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Exercise Intervention on Various Physiologic Factors That Change With Increasing Age

NCT00283673
View directory record Official record
Conditions
Aging
Interventions
Exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 1998
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

Overnight Closed Loop Study in U.S.

NCT01857973
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Hybrid Closed Loop
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Escondido, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

NCT01896856
View directory record Official record
Conditions
Previously Treated Metastatic Colorectal Cancer
Interventions
SGI-110 Dose Escalation, Regorafenib, TAS-102, SGI-110, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 30, 2026, 8:23 PM EDT
Enrolling by invitation Not applicable Interventional

Cognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability

NCT02914951
View directory record Official record
Conditions
Autism, Intellectual Disability
Interventions
Cognitive-Behavioral Therapy, Functional magnetic resonance imaging (fMRI)
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
8 Years to 16 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Early Phase 1 Interventional Results available

Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure

NCT03446651
View directory record Official record
Conditions
Heart Failure
Interventions
Lysine Chloride, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Satisfaction With Subdissociative Dose Ketamine Versus Morphine for Emergency Department Pain Control

NCT04698772
View directory record Official record
Conditions
Abdominal Pain
Interventions
Ketamine, Morphine
Drug
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 30, 2026, 8:23 PM EDT
Withdrawn Not applicable Interventional

Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO

NCT03673566
View directory record Official record
Conditions
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less), Neonatal Infection, Satisfaction, Stress, Chronic Lung Disease, Growth Acceleration, Adverse Event
Interventions
NICU Dashboard
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT01390545
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Veltuzumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
La Mesa, California • Los Angeles, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

NCT05526157
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trauma-informed Personalized Scripts (TIPS) for Relationship Abuse

NCT02782728
View directory record Official record
Conditions
Violence, Abuse
Interventions
TIPS-Plus, TIPS-Basic
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years to 29 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 30, 2026, 8:23 PM EDT
Recruiting Not applicable Interventional

Brief Smartphone Treatment Study

NCT04846777
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Mindfulness ecological momentary intervention, Self-monitoring placebo
Device
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Immulina on Immune Measures

NCT04071730
View directory record Official record
Conditions
Effects of Immulina on Natural Killer Cells
Interventions
Immulina Dietary Supplementation
Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 30, 2026, 8:23 PM EDT
Recruiting Not applicable Interventional

Targeting Cervical Epidural Spinal Cord Stimulation for Functional Recovery

NCT06701422
View directory record Official record
Conditions
Cervical Spinal Cord Injury, Tetraplegia/Tetraparesis, Cervical Myelopathy
Interventions
Intraoperative stimulation of the cervical spinal cord
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational

XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery

NCT00731237
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Huntsville, Alabama • Mesa, Arizona • Hot Springs, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2009 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 2 Interventional Results available

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

NCT03457701
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Phase 1Phase 2 Interventional

Open-label Extension Study of ADP101

NCT05243719
View directory record Official record
Conditions
Food Allergy
Interventions
ADP101
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 57 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 30, 2026, 8:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

NCT04503265
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Interventions
AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
Drug
Lead sponsor
AtlasMedx, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Phase 1Phase 2 Interventional

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

NCT04843319
View directory record Official record
Conditions
Advanced Prostate Adenocarcinoma
Interventions
VERU-100
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Tucson, Arizona • San Bernardino, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 30, 2026, 8:23 PM EDT
Not listed Not applicable Interventional

PALS-CATCH Intervention for Obesity Prevention Among At-risk Toddlers

NCT02739334
View directory record Official record
Conditions
Childhood Obesity
Interventions
ENRICH, Control - monthly handouts
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
24 Months to 48 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 3 Interventional Results available

3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency

NCT04228445
View directory record Official record
Conditions
Ureter Injury
Interventions
3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%, Saline spray
Drug
Lead sponsor
Prove pharm
Industry
Eligibility
18 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 30, 2026, 8:23 PM EDT